SCHEMBL2013652

SCHEMBL2013652

O=C(NCC(=O)c1c(O)cc(O)cc1OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTT P42858 1/20 0.44
SLC5A1 P13866 2/20 0.44
SLC5A2 P31639 2/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
TGM2 P21980 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PLAU P00749 1/20 0.42
PTPN1 P18031 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007189 0.89 MEN1 (0.47) LMNASMN1; SMN2HTTSLC5A1SLC5A2
SCHEMBL2010496 0.83 HPGD (0.45) SMN1; SMN2MAPTALDH1A1CTSLCTSB
SCHEMBL30929737 0.77 SLC5A1 (0.55) LMNASLC5A1SLC5A2GAAMAPT
SCHEMBL30789227 0.76 MAOB (0.56) LMNASMN1; SMN2SLC5A1SLC5A2GAA
SCHEMBL14616693 0.76 MAOB (0.56) LMNASMN1; SMN2SLC5A1SLC5A2GAA
SCHEMBL2013202 0.76 HPGD (0.44) MAPTALDH1A1CTSLCTSBCTSS
SCHEMBL21480733 0.74 HTT (0.51) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL3230023 0.74 LMNA (0.59) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL30929747 0.73 SLC5A1 (0.53) LMNASLC5A1SLC5A2GAAMAPT
SCHEMBL7765686 0.72 LMNA (0.61) LMNASMN1; SMN2HTTALDH1A1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 LMNA 2984/4885SMN1; SMN2 4690/4885HTT 1966/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 LMNA 2984/4885SMN1; SMN2 4690/4885HTT 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.